Barry Morse, PhD
Barry Morse has over 20 years of experience in both large pharma and small biotech environments. He has led groups in both cell therapy and large molecule organizations that produced early therapeutic leads, and has expertise in multiple therapeutic areas, including Oncology, Immunology, and Infectious Disease. In his career, he has often served as the connecting point between discovery and early development, developing an understanding of how both of these organizations work, and how to best bridge the gaps between them. Barry is well-versed in the assay development and preclinical functional assays that are necessary from compound screening through early development.
-
Cell Therapy - Head of IPSC Biology at Century Therapeutics
One of the original team that started Century, and built the IPSC Biology group. Lead the initial differentiation protocol development and candidate selection for CNTY-101, Century’s clinical IPSC derived NK candidate for B cell lymphoma.
-
Therapeutic Antibodies - Head of Protein Expression, Biologics Research Janssen R&D
Lead the Protein Expression Team within the Biologics Research organization. Developed methods and processes to optimize and express therapeutic proteins for high throughput screening, and at scales sufficient for animal studies.
-
Cell Line Development - Janssen Pharmaceutical Development
Led efforts to evaluate new technologies and optimize expression of therapeutic antibodies in manufacturing cell lines.